Ligand-dependent nuclear receptor corepressor (LCOR)

LCOR is a transcriptional corepressor widely expressed in fetal and adult tissues, recruited to agonist-bound nuclear receptors via a conserved LXXLL motif. It attenuates receptor-mediated transactivation, as in inhibition of estrogen- and progesterone receptor–mediated gene expression in breast cancer cells. LCOR modulates gene expression by engaging histone deacetylases and C-terminal binding proteins, represses cell cycle regulators like p21, and interacts with other transcription factors such as KLF6. Its downregulation is associated with increased stem cell properties and resistance to differentiation, relevant in cancer progression. LCOR also functions in non-classical nuclear receptor signaling, such as priming interferon responses and regulating osteogenic versus adipogenic fate in stem cells. In prostate cancer, LCOR represses androgen receptor signaling, and loss of this repression associates with disease progression. LCOR's prognostic significance in cancer and its regulatory role in transcription make it a potential biomarker and target for future therapeutic strategies.

Other names

Ligand-dependent corepressorLCORC10orf12KIAA1795MLR2FLJ38026DKFZP564P1916FLJ13022Mblk1-related protein 2

HDAC-dependent transcriptional repression; HDAC-independent repression; Interaction with C-terminal binding proteins (CtBP); Inhibition of ligand-induced nuclear receptor transactivation